SEC Form 4 · accession 0000912282-26-000893
Aptose Biosciences Inc. · APTOF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rafael Bejar
Other
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000882361
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jun 30, 2026 | D | 244 | $1.72 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $2.00 | Jun 30, 2026 | D | 35,000 | D | — | Feb 5, 2034 | Common Shares | 35,000 | 0 | D |
| Employee Stock OptionF3 | $0.66 | Jun 30, 2026 | D | 200,000 | D | — | Jan 19, 2033 | Common Shares | 200,000 | 0 | D |
| Performance Stock OptionF4 | $2.35 | Jun 30, 2026 | D | 400,000 | D | — | Aug 19, 2031 | Common Shares | 400,000 | 0 | D |
| Employee Stock Option (Right to Buy)F3 | $4.37 | Jun 30, 2026 | D | 343,000 | D | — | Jan 4, 2031 | Common Shares | 343,000 | 0 | D |
| Employee Option GrantF3 | $6.91 | Jun 30, 2026 | D | 200,000 | D | — | Jan 30, 2030 | Common Shares | 200,000 | 0 | D |
| Employee Stock Option (Right to Buy)F3 | $5.67 | Jun 30, 2026 | D | 400,000 | D | — | Dec 31, 2030 | Common Shares | 400,000 | 0 | D |
Explanation of responses
- F1Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
- F2Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
- F3Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
- F4Performance stock options subject to specific performance criteria.
Remarks
TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF HTE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/26/25 AND ISSUER'S 1:15 REVERSE STOCK SPLIT ON 6/6/23